Stage 4 Cancer Strategies That Truly Make a Difference
Research on angiogenesis for stage 4 cancer – the method by which tumors attract blood vessels to nourish themselves was begun by Dr. Judah Folkman, who determined that a tumor placed in a lab container had a limited potential for growth. Moreover, he established that the micro vascular network for the cancer could be disrupted. Like so many great scientific minds with a new idea, Folkman was often ignored by his colleagues and peers. While it should be said that many agreed there was evidence of newly formed vessels – the dissenting assumption was that the detected inferior cell networks were merely a byproduct of dying tumor cells. Some years later Folkman could prove that they, in fact, were actually being created by the cancer cells as a means to deliver them there much-needed nutrients. Now consider this for a moment. The United States Government website HealthReport.gov contends that, “Nearly one out of two Americans born today will be diagnosed with cancer at some point in their lifetime. About 1,596,670 new cancer, cases are expected to be diagnosed in 2011 – and about 571,950 Americans are expected to die of cancer, more than 1,500 people a day – and cancer is the second most common cause of death in the US, exceeded only by heart disease. In the US, cancer alone accounts for nearly 1 of every 4 deaths." Stage 4 cancer patients are also growing in number due to late diagnosis and often non effect treatment methods.
With such a destructive epidemic facing us, one would think that new ideas and innovation would be welcomed with open arms. Nevertheless, we regularly and have even come to expect the all-to-familiar pattern of contempt for ground-breaking innovators and thinkers. In another example, devoted researcher Dr. Don Ingber was studying endothelial cells when one of his test samples became contaminated with a fungus. He was amazed to see that in the presence of this fungus, the cells actually stopped growing. As fate would have it, Ingber’s original position that angiogenesis could be inhibited was ultimately supported. Today anti-angiogenic drugs are a multibillion-dollar pharmaceutical industry and doctors like Folkan and Ingber, should receive far greater commendation for their works – rather than the usual condemnation. Many o of these anti-angiogenic chemotherapeutic drugs are used to manage stage 4 cancer patients. Anti-angiogenic drugs such as sorafenib (Nexavar®), sunitinib (Sutent®), pazopanib (Votrient®), and everolimus (Afinitor®) are typically prescribed in late-stage cancers in order to slow growth. However, a simple agent like oxygen (non patentable) is an often overlooked for the dominant anti-angiogenic agent that it is. In fact, oxygen metabolism errors are involved in the cause and development of many cancers. These strategies culminate with more than a decade of combining conventional and advanced natural approaches to treat cancer. Understanding the role of oxygen and using is correctly is vital for success, particularly when treating stage 4 cancer. In light of such grim aforementioned statistics, it is imperative that we must work collectively and with open minds to defeat the venerable adversary called cancer and provided better methods for tackling stage 4 cancer. Through all of the struggles some bright lights have emerged – and perhaps this one has its place among the brightest - anti-antiogenic therapy. In simple terms, it is designed to starve stage 4 cancer from much needed nutrients thereby blocking its development, growth, and spread. This is revolutionary when one considers that 90 percent of cancer patients succumb to their disease because their cancer has spread beyond its original site (metasized) – the picture of stage 4 cancer diagnosis. The fact that we may now inhibit tumor angiogenesis – is a quantum leap for treatment protocols. While such treatments are viewed as being in their fledgling states by conventional institutions, Envita has already realized stunning success with them. In fact, it has been found that integrating these anti-angiogenic methods with traditional chemotherapy and radiation can work synergistically with the body and produce impressive results. These methods seem to be very helpful for advanced stage 4 cancer patients as well.
Because of the incredible threat it imposes, there is no question that angiogenesis should be blocked to stop tumor growth. In fact, without it, tumor growth is limited to a miniscule 2 mm in size. Envita’s specifically designed cancer therapies work by shutting off nutrients to the tumors and ultimately destroy the cancer cells that rely on them. In addition to this approach a protein known as VEGF (*vascular endothelial growth factor) has been identified as the agent that stimulates angiogenesis. It has been found that a tumor releases VEGF for a variety of factors - one of which is triggered by a lack of oxygen, or hypoxia. This process is brought into being by the transcriptional factor HIF-1 (hypoxia inducible factor 1). One thing we can count on is that a tumor will always attempt to grow, even beyond the support of its existing blood supplies. As a result there is always a need for hypoxic tissue on the tumor so it can create more VEGF. That alone is enough to suggest to Envita that correcting a tumor’s oxygen metabolism will likely yield positive results. You see, without VEGF tumors simply cannot grow or spread. By introducing reactive oxygen species, it is possible to potentiate other cancer treatments as they stimulate a change from anaerobic to aerobic that a tumor, by nature, will detest. Creating an environment that naturally repels stage 4 cancer is a critical method by which to facilitate and maintain remission. But how can this be done effectively? Well, VEGF has been shown to bind to certain cells, called endothelials, of the nearby blood vessels. These cells diverge and grow in the direction of the tumor forming new, albeit inferior blood vessels that actually rely on VEGF to survive. As fate would have it, they are not as difficult as one might think to detect. So, the goal then becomes targeting and destroying these rogue vessels while bolstering healthy ones. The end result accelerates energy, cardiovascular stamina, and the patient’s overall endurance. It has been determined that VEGF is connected to a broad series of tumor types, including breast, ovarian, cervical, esophageal, lung, and cervical cancer, as well as glioblastoma multiforme and renal cell carcinoma. It would seem that VEGF emissions may also hinder the immune system’s ability to react and fight off the tumor - regularly occurring in stage 4 cancers. Remember, the immune system is our first and last defense against stage 4 cancers. While many patients believe that their cancer has been destroyed they often find out that dormant metastasis was biding its time to strike. We can however attempt to thwart its efforts by correcting the body’s oxygen metabolism – thereby stopping angiogenesis in its tracks.
If you know anyone who has been diagnosed with cancer or has stage 4 cancer, please forward this article to them. We at Envita welcome you to contact us with questions and invite you to watch our informative videos. You can also visit our PPMR section to learn more about the power of our personalized medicine for cancer and chronic diseases. It is important information that may save lives. Education is the best prescription. Take advantage of Envitaâ€™s Comprehensive Smart Oncology (link to Envita.com cancer section) which incorporates the foremost treatment approaches and synchronizes them with aggressive natural therapies to help each patient far greater results. Visit Envitaâ€™s stage 4 cancer (link to Envita cancer section) therapies and strategies. References: *Judah Folkman <http://www.pbs.org/wgbh/nova/body/cancer-warrior.html > , < http://en.wikipedia.org/wiki/Judah_Folkman > *Stage 4 Cancer < http://en.wikipedia.org/wiki/Stage-4_cancer#Systems_of_staging > * Vascular endothelial growth factor <http://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor>*HealthReform.gov <http://www.healthreform.gov/reports/fightingcancer/index.html>*American Cancer Society <http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/docu ment/acspc-029771.pdf>